Menarini Group and Ryvu Therapeutics Announce First Clinical Data from the Phase II JASPIS-01 Study of dapolsertib (MEN1703, SEL24) in Heavily Pretreated Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma at the 2026 ASH Annual Meeting

Initial Phase II JASPIS-01 results showed clinical activity for dapolsertib monotherapy in heavily pretreated patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma; the population had a median of four prior therapy lines, and 53% had received CAR-T while 60% had received CD3×CD20 bispecific antibodies. The safety profile was described as manageable at the intended dose of 125 mg orally once daily on days 1–14 of 21-day cycles. The preliminary data will be presented at ASH on December 13, 2026; dapolsertib remains investigational and is not approved.

Analysis

For Ryvu, the key economic distinction is that Menarini funds dapolsertib development and holds global rights: this reduces Ryvu’s direct cash-burn exposure, but the equity value sensitivity depends on royalty and milestone terms not disclosed here. The announcement therefore supports pipeline optionality more clearly than near-term revenue or a change in Ryvu’s financing profile.

The signal remains weakly positive, not yet efficacy validation. “Clinical activity” without ORR, response duration, cohort size, follow-up, or grade-specific safety data is not enough to compare dapolsertib with established salvage approaches or to estimate addressable uptake. The post-CAR-T/bispecific population is an unmet-need niche, but it may also be biologically difficult and commercially narrower than the headline implies. A positive monotherapy readout could improve the rationale for the combination cohort; it does not establish combination benefit.

Near term, the December ASH presentation is a discrete volatility catalyst, with risk that the abstract’s limited detail has already captured much of the announcement response. Over 1–3 months, focus on full response and durability data, not the “first-in-class” framing. Over 6–18 months, value depends on reproducibility, expansion/combination progress, and whether Menarini advances the program. Falsifiers are a low or short-lived response signal, dose-limiting toxicity, stalled enrollment/development, or contractual economics that leave Ryvu with little participation.

Key Decisions for Investors

• Treat RVU as a catalyst watch rather than a fundamental re-rating today. Before sizing any position, verify the JASPIS-01 Group 2 sample size, ORR, duration of response, follow-up, and safety details in the ASH poster.
• If RVU weakens on the initial headline, consider only a small, defined-risk event position ahead of the December 13 presentation; avoid adding until efficacy and durability are quantifiable. A thinly detailed abstract or an adverse full-data reaction is a reason to exit, not average down.
• Check Ryvu’s license agreement for milestone and royalty economics and monitor Menarini’s subsequent development commitments. These determine whether clinical success translates into material value for RVU shareholders.
• Do not infer a broad threat to CAR-T or CD3×CD20 bispecific franchises from this early monotherapy signal. Reassess only if later data show durable responses in patients refractory to those modalities and development advances toward a registrational path.